» Articles » PMID: 35884447

A New Possible Cut-Off of Cytokeratin 19 MRNA Copy Number by OSNA in the Sentinel Node of Breast Cancer Patients to Avoid Unnecessary Axillary Dissection: A 10-Year Experience in a Tertiary Breast Unit

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 27
PMID 35884447
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: The main discriminant in breast cancer prognosis is axillary lymph node status. In a select cohort of patients, axillary lymph node dissection (ALND) may be safely spared. This study aimed to determine a new possible cut-off of cytokeratin (CK) 19 mRNA copy number in the SLN to predict cases at high risk of positive ALND. (2) Methods: Clinical records of 1339 patients were retrospectively reviewed and were separated into two groups according to the axillary status (negative: ALNs- and positive ALNs+). Receiver operative characteristic (ROC) curves were used to identify a new optimal cut-off of CK19 mRNA copy number in SLN; (3) Results: Large tumor size and high grade were found mostly in ALNs+. Results from the ROC analyses, with an AUC of 82.1%, identified a new cut-off (9150 CK19 mRNA copies) showing 94% sensitivity, 67.3% specificity, 61.2% positive, and 95.3% negative predictive values; (4) OSNA remains the most-important intra-operative tool to identify patients who can benefit from ALND but with the traditional cut-off, many patients undergo needless ALND. The results of the present study suggest a new cut-off helpful to personalize surgical treatment and avoid unnecessary invasive procedures.

Citing Articles

Application of the OSNA Technique (One-Step Nucleic Acid Amplification Test) in Breast Cancer.

Sychowski G, Romanowicz H, Smolarz B Int J Mol Sci. 2025; 26(2).

PMID: 39859370 PMC: 11766269. DOI: 10.3390/ijms26020656.


Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.

Fan Y, Li J, Zhu D, Zhu H, Zhao Y, Zhu X BMC Surg. 2023; 23(1):209.

PMID: 37495945 PMC: 10369839. DOI: 10.1186/s12893-023-02101-8.

References
1.
Giuliano A, Ballman K, McCall L, Beitsch P, Brennan M, Kelemen P . Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017; 318(10):918-926. PMC: 5672806. DOI: 10.1001/jama.2017.11470. View

2.
Meretoja T, Audisio R, Heikkila P, Bori R, Sejben I, Regitnig P . International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat. 2013; 138(3):817-27. DOI: 10.1007/s10549-013-2468-3. View

3.
Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

4.
Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Yanagisawa A . Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer. 2011; 117(19):4365-74. DOI: 10.1002/cncr.26060. View

5.
Degnim A, Griffith K, Sabel M, Hayes D, Cimmino V, Diehl K . Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003; 98(11):2307-15. DOI: 10.1002/cncr.11803. View